<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452803</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-06-164</org_study_id>
    <nct_id>NCT00452803</nct_id>
  </id_info>
  <brief_title>Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Randomized Phase II Study Preoperative Chemotherapy Versus Preoperative Concurrent Chemoradiotherapy for Patients With Biopsy-Proven N2 Stage IIIA Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is suggested that a bimodal or trimodal approach combining neoadjuvant chemotherapy with&#xD;
      or without radiotherapy followed by surgery provides a potentially superior method of&#xD;
      enhancing resectability and improving locoregional control and survival compared to&#xD;
      radiotherapy alone followed by surgery. Unsolved questions are the identification of the best&#xD;
      induction strategy, the impact of surgery on long-term survival, and the contribution of&#xD;
      radiation therapy in this setting. Thus, the investigators conduct a phase II trial to&#xD;
      compare neoadjuvant chemotherapy with concurrent chemoradiotherapy in patients with biopsy&#xD;
      proven N2 stage IIIA NSCLC to address optimal induction strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperative Therapy Arm 1. (preoperative chemotherapy) Paclitaxel (90 mg/m2)on day 1 and 8&#xD;
      Cisplatin (40 mg/m2)on day 1 and 8. q 3 weeks, 2 cycles&#xD;
&#xD;
      Arm 2. (preoperative chemoradiotherapy) Paclitaxel (50 mg/m2)on day 1, 8, 15, 22 &amp; 29&#xD;
      Cisplatin (20 mg/m2)on day 1, 8, 15, 22 &amp; 29. Thoracic radiation therapy (TRT) 1.8 Gy daily,&#xD;
      five times per week (45 Gy target dose in 5 weeks).&#xD;
&#xD;
      Postoperative Consolidation Chemotherapy:&#xD;
&#xD;
      Paclitaxel (90 mg/m2) on day 1 and 8. Cisplatin (40 mg/m2) on day 1 and 8. q 3weeks, 2 cycles&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the time to recurrence</measure>
    <time_frame>The interval from the date of randomization to the date to the date of the first objective evidence of recurrence or to the date of death, if before recurrence</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the overall survival</measure>
    <time_frame>from the date of randomization to the date of death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pathologic complete response rate and the complete resection rate</measure>
    <time_frame>After surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate toxicities</measure>
    <time_frame>from the first date of treatment to 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>study arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pre-operative chemotherapy (Pac/Cis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-operative concurrent chemoradiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 &amp; 8 q 3weeks, Pre-OP &amp; post-op : 2cycles (total 4 cycles)</description>
    <arm_group_label>study arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent chemoradiation therapy</intervention_name>
    <description>Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 &amp; 8 q 3weeks, Pre-OP &amp; post-op : 2cycles (total 4 cycles)</description>
    <arm_group_label>study arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Concurrent chemoradiation therapy</intervention_name>
    <description>Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx</description>
    <arm_group_label>study arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologic or cytologic diagnosis of non-small cell lung cancer.&#xD;
&#xD;
          2. Presence of biopsy-proven N2 stage IIIA, according to the American Joint Committee on&#xD;
             Cancer (AJCC), with none of the mediastinal lymph nodes &gt; 3 cm in largest diameter.&#xD;
&#xD;
          3. Tumor amenable to surgical resection.&#xD;
&#xD;
          4. At least one unidimensional measurable lesion meeting Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST. 2000).&#xD;
&#xD;
          5. No prior tumor therapy (surgery, radiotherapy, chemotherapy, immunotherapy, or any&#xD;
             other type of tumor therapy).&#xD;
&#xD;
          6. Performance status of 0-1 on ECOG scale.&#xD;
&#xD;
          7. At least 18 years old.&#xD;
&#xD;
          8. Patient compliance that allows adequate follow-up.&#xD;
&#xD;
          9. Medical fitness of patients adequate for radical NSCLC surgery.&#xD;
&#xD;
         10. Adequate organ function including the following:Adequate hematologic function: WBC&#xD;
             count ≥ 4,000/uL, absolute neutrophil count (ANC) ≥ 1,500/uL, platelet count ≥&#xD;
             100,000/uL, and hemoglobin ≥ 10 gm/dL.Adequate hepatic function: bilirubin ≤ 1.5 x&#xD;
             UNL, ALT or AST ≤ 2.5 x UNL.Adequate renal function: creatinine ≤ 1.5mg/dL.&#xD;
&#xD;
         11. Signed informed consent from patient or legal representative.12. Patients with&#xD;
             reproductive potential must use an approved contraceptive method during and for 3&#xD;
             months after the study. Females with childbearing potential must have a negative urine&#xD;
             hCG test within 7 days prior to study enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent administration of any other tumor therapy, including radiotherapy,&#xD;
             chemotherapy, immunotherapy.&#xD;
&#xD;
          2. Active uncontrolled infection.&#xD;
&#xD;
          3. Serious concomitant disorders that would compromise the safety of patient or&#xD;
             compromise the patient's ability to tolerate therapy.&#xD;
&#xD;
          4. MI within preceding 6 months or symptomatic heart disease including unstable angina,&#xD;
             congestive heart failure, or uncontrolled arrhythmia.&#xD;
&#xD;
          5. Significant neurological or mental disorder.&#xD;
&#xD;
          6. Second primary malignancy.&#xD;
&#xD;
          7. Pregnant or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heung Tae Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heung Tae Kim, M.D.</last_name>
    <phone>+82-31-920-1602</phone>
    <email>htkim@ncc.re.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>411-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jae-Ill Zoo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jong Mog Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moon Soo Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun-Sung Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Soo Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji-Youn Han, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kwan Ho Cho, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong Ryull Pyo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bin Hwangbo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hee Seok Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyae Young Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geon Kook Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moon Woo Seong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyeong-Man Hong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byung-Ho Nam, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tak Yun, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2007</study_first_posted>
  <last_update_submitted>July 9, 2010</last_update_submitted>
  <last_update_submitted_qc>July 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Heung Tae Kim</name_title>
    <organization>National Cancer Center, Korea</organization>
  </responsible_party>
  <keyword>Non small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

